<!DOCTYPE html>
<html lang="pt-BR">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Hipertens√£o Arterial (DBHA 2025)</title>
    <link rel="stylesheet" href="style.css">
    <style>
        /* Estilos Internos Espec√≠ficos para Resumos */
        :root { --theme-has: #D32F2F; } 
        
        .resumo-box {
            background: white;
            border-radius: 12px;
            padding: 20px;
            margin-bottom: 20px;
            box-shadow: 0 2px 6px rgba(0,0,0,0.04);
            border-left: 5px solid var(--theme-has);
        }

        .res-header { 
            font-size: 1.1rem; 
            font-weight: 800; 
            margin-bottom: 15px; 
            display: flex; 
            align-items: center; 
            gap: 10px; 
            color: #B71C1C; 
            text-transform: uppercase;
            letter-spacing: 0.5px;
            border-bottom: 1px solid #FFEBEE;
            padding-bottom: 10px;
        }

        .res-content { font-size: 0.95rem; color: #444; line-height: 1.6; }
        
        /* Tabelas Gerais */
        .table-custom { width: 100%; border-collapse: collapse; margin: 10px 0; font-size: 0.85rem; }
        .table-custom th { background-color: #FFEBEE; color: #B71C1C; padding: 8px; text-align: left; border: 1px solid #FFCDD2; }
        .table-custom td { padding: 8px; border: 1px solid #eee; }
        .table-custom tr:nth-child(even) { background-color: #FAFAFA; }

        /* Tabela de Risco (Matriz Fidedigna ao DOCX) */
        .table-risk { width: 100%; border-collapse: collapse; font-size: 0.75rem; text-align: center; margin-top: 15px; border: 1px solid #ccc; }
        .table-risk th { background: #424242; color: white; padding: 8px; border: 1px solid #666; vertical-align: middle; font-weight: bold; }
        .table-risk td { padding: 10px 5px; border: 1px solid #999; font-weight: bold; color: #000; vertical-align: middle; text-transform: uppercase; }
        
        .risk-row-header { background-color: #f5f5f5; color: #333; text-align: left; font-weight: bold; padding-left: 10px; min-width: 150px; }

        /* Cores de Risco */
        .risk-low { background-color: #81C784; } 
        .risk-mod { background-color: #FFD54F; } 
        .risk-high { background-color: #EF5350; color: white !important; }
        .risk-very-high { background-color: #880E4F; color: white !important; }

        /* Lista de Fatores */
        .frcv-list { display: block; font-size: 0.85rem; margin-bottom: 15px; background: #FFF3E0; padding: 10px; border-radius: 8px; border: 1px solid #FFE0B2; }
        .frcv-item { margin-bottom: 5px; display: block; line-height: 1.4; }
        .frcv-item::before { content: "‚Ä¢ "; color: #D32F2F; font-weight: bold; }

        /* Boxes de Destaque */
        .alert-prevent { background: #E3F2FD; border: 1px solid #BBDEFB; color: #0D47A1; padding: 12px; border-radius: 8px; margin-top: 15px; font-size: 0.9rem; }
        .step-box { background: #FAFAFA; padding: 12px; border-radius: 8px; margin-bottom: 10px; border-left: 4px solid #555; }
        .step-num { display: inline-block; background: #333; color: white; padding: 2px 8px; border-radius: 4px; font-size: 0.8rem; font-weight: bold; margin-bottom: 5px; }

        /* Tabela Drogas */
        .drug-table { width: 100%; font-size: 0.85rem; margin-bottom: 20px; border-collapse: collapse; }
        .drug-table th { background: #ECEFF1; color: #37474F; text-align: left; padding: 8px; border-bottom: 2px solid #CFD8DC; }
        .drug-table td { border-bottom: 1px solid #eee; padding: 8px; vertical-align: top; }
        .drug-name { font-weight: 700; color: #D32F2F; display: block; font-size: 0.9rem; }
        .drug-class-info { background: #FFFDE7; color: #F57F17; padding: 8px; font-size: 0.85rem; border-bottom: 1px solid #eee; font-style: italic; border-left: 4px solid #FBC02D; margin-bottom: 0; }
        
        .tag-sus { background-color: #2E7D32; color: white; padding: 2px 6px; border-radius: 4px; font-size: 0.65rem; font-weight: bold; margin-left: 5px; vertical-align: middle; display: inline-block; }

        .ref-section { margin-top: 40px; font-size: 0.75rem; color: #777; border-top: 1px solid #ddd; padding-top: 20px; }
    </style>
</head>
<body>

    <header class="app-header">
        <button class="back-btn" onclick="window.location.href='resumos.html'">‚¨Ö</button>
        <div class="app-title">Hipertens√£o (DBHA 2025)</div>
    </header>

    <div class="container">

        <div class="resumo-box">
            <div class="res-header">ü©∫ Diagn√≥stico e Classifica√ß√£o</div>
            <div class="res-content">
                <p style="font-size:0.85rem; margin-bottom:10px;">Valores para medidas de consult√≥rio (adultos > 18 anos). Confirmar em &ge; 2 consultas.</p>
                <table class="table-custom">
                    <tr><th>Classifica√ß√£o</th><th>PAS (mmHg)</th><th>PAD (mmHg)</th></tr>
                    <tr><td><strong>PA √ìtima</strong></td><td>< 120</td><td>e < 80</td></tr>
                    <tr><td><strong>Pr√©-Hipertens√£o</strong></td><td>120 ‚Äì 139</td><td>e/ou 80 ‚Äì 89</td></tr>
                    <tr><td><strong>HAS Est√°gio 1</strong></td><td>140 ‚Äì 159</td><td>e/ou 90 ‚Äì 99</td></tr>
                    <tr><td><strong>HAS Est√°gio 2</strong></td><td>160 ‚Äì 179</td><td>e/ou 100 ‚Äì 109</td></tr>
                    <tr><td><strong>HAS Est√°gio 3</strong></td><td>&ge; 180</td><td>e/ou &ge; 110</td></tr>
                </table>
            </div>
        </div>

        <div class="resumo-box">
            <div class="res-header">‚öñÔ∏è Estratifica√ß√£o de Risco CV</div>
            <div class="res-content">
                <h4 style="color:#B71C1C; font-size:0.9rem; margin-bottom:5px;">Fatores de Risco Cardiovascular (FRCV):</h4>
                <div class="frcv-list">
                    <span class="frcv-item">Sexo masculino.</span>
                    <span class="frcv-item">Idade: > 55 anos (H) e > 65 anos (M).</span>
                    <span class="frcv-item">Hist√≥ria Familiar Prematura (1¬∫ grau): < 55 anos (H) e < 65 anos (M).</span>
                    <span class="frcv-item">Tabagismo.</span>
                    <span class="frcv-item">Obesidade (IMC &ge; 30 kg/m¬≤).</span>
                    <span class="frcv-item">Dislipidemia: LDL-c &ge; 100; n√£o-HDL &ge; 130; HDL-c &le; 40(H)/&le; 50(M); TG > 150 mg/dL.</span>
                </div>

                <div style="overflow-x:auto;">
                    <table class="table-risk">
                        <thead>
                            <tr>
                                <th rowspan="2" class="risk-row-header" style="background:#424242; color:white; text-align:center;">Fatores de risco CV, presen√ßa de LOA ou DCV</th>
                                <th colspan="4" style="background:#555;">Press√£o Arterial (mmHg)</th>
                            </tr>
                            <tr><th width="18%">PAS 130-139<br>PAD 80-89</th><th width="18%">HA Est√°gio 1</th><th width="18%">HA Est√°gio 2</th><th width="18%">HA Est√°gio 3</th></tr>
                        </thead>
                        <tbody>
                            <tr><td class="risk-row-header">Sem fatores de risco CV</td><td class="risk-low">RISCO BAIXO</td><td class="risk-low">RISCO BAIXO</td><td class="risk-mod">RISCO MODERADO</td><td class="risk-high">RISCO ALTO</td></tr>
                            <tr><td class="risk-row-header">1 ou 2 fatores de risco CV</td><td class="risk-low">RISCO BAIXO</td><td class="risk-mod">RISCO MODERADO</td><td class="risk-high">RISCO ALTO</td><td class="risk-high">RISCO ALTO</td></tr>
                            <tr><td class="risk-row-header">&ge; 3 fatores de risco CV</td><td class="risk-mod">RISCO MODERADO</td><td class="risk-high">RISCO ALTO</td><td class="risk-high">RISCO ALTO</td><td class="risk-high">RISCO ALTO</td></tr>
                            <tr><td class="risk-row-header">LOA, DRC Est√°gio 3 ou DM</td><td class="risk-high">RISCO ALTO</td><td class="risk-high">RISCO ALTO</td><td class="risk-high">RISCO ALTO</td><td class="risk-very-high">RISCO MUITO ALTO</td></tr>
                            <tr><td class="risk-row-header">DCV estabelecida ou DRC Est√°gio &ge; 4</td><td class="risk-very-high">RISCO MUITO ALTO</td><td class="risk-very-high">RISCO MUITO ALTO</td><td class="risk-very-high">RISCO MUITO ALTO</td><td class="risk-very-high">RISCO MUITO ALTO</td></tr>
                        </tbody>
                    </table>
                </div>
                
                <div class="alert-prevent">
                    <strong>üì¢ Escore PREVENT (AHA):</strong> Recomendado para refinar a estratifica√ß√£o em pacientes sem doen√ßa manifesta (Risco em 10 anos).<br>
                    <strong>Baixo:</strong> < 5% | <strong>Lim√≠trofe:</strong> 5 a 7,5% | <strong>Intermedi√°rio:</strong> 7,5 a 20% | <strong>Alto:</strong> &ge; 20%
                </div>
            </div>
        </div>

        <div class="resumo-box">
            <div class="res-header">üö¶ Indica√ß√£o de Tratamento</div>
            <div class="res-content">
                <table class="table-custom">
                    <tr><th width="40%">Classifica√ß√£o / Risco</th><th>Conduta Recomendada</th></tr>
                    <tr><td><strong>PAS 130-139 e/ou<br>PAD 85-89</strong></td><td>In√≠cio imediato de <strong>MEV</strong>.<br>Considerar medicamento se <strong>Alto Risco CV</strong> ou preven√ß√£o secund√°ria.</td></tr>
                    <tr><td><strong>Est√°gio 1 (Risco Baixo)</strong></td><td><strong>MEV</strong> por 3 meses. Se n√£o meta: Farmacoterapia.</td></tr>
                    <tr><td><strong>Est√°gio 1 (Mod/Alto)</strong></td><td><strong>MEV + Farmacoterapia</strong> imediata.</td></tr>
                    <tr><td><strong>Est√°gio 2 e 3</strong></td><td><strong>MEV + Combina√ß√£o de f√°rmacos</strong> imediata.</td></tr>
                    <tr><td><strong>Idosos Fr√°geis</strong></td><td>Cautela. Iniciar se PAS &ge; 160 (ou &ge; 140). Monoterapia.</td></tr>
                </table>
            </div>
        </div>

        <div class="resumo-box">
            <div class="res-header">üíä Tratamento Farmacol√≥gico</div>
            <div class="res-content">
                
                <h4 style="color:#00796B; margin-top:15px; margin-bottom:0;">1. Diur√©ticos (D)</h4>
                <div class="drug-class-info"><strong>Obs. Classe:</strong> Doses maiores aumentam efeitos metab√≥licos sem ganho anti-hipertensivo adicional. Tiaz√≠dicos e similares (Hidroclorotiazida, Clortalidona, Indapamida) s√£o <strong>contraindicados em gota ativa</strong>.</div>
                <table class="drug-table">
                    <tr><th>F√°rmaco</th><th>Dose (mg)</th><th>x/dia</th><th>Obs</th></tr>
                    <tr><td><span class="drug-name">Hidroclorotiazida <span class="tag-sus">SUS</span></span></td><td>25 ‚Äì 50</td><td>1</td><td></td></tr>
                    <tr><td><span class="drug-name">Clortalidona</span></td><td>12,5 ‚Äì 25</td><td>1</td><td>Maior pot√™ncia/meia-vida.</td></tr>
                    <tr><td><span class="drug-name">Indapamida</span></td><td>1,5 ‚Äì 3,0</td><td>1</td><td>Metabolicamente neutra.</td></tr>
                    <tr><td><span class="drug-name">Furosemida <span class="tag-sus">SUS</span></span></td><td>20 ‚Äì 240</td><td>1 a 3</td><td>Uso em DRC (ClCr < 30) ou Edema. Curta a√ß√£o.</td></tr>
                    <tr><td><span class="drug-name">Espironolactona <span class="tag-sus">SUS</span></span></td><td>25 ‚Äì 100</td><td>1 a 2</td><td>Poupador K+. 4¬™ droga na HAS resistente. Risco ginecomastia.</td></tr>
                    <tr><td><span class="drug-name">Eplerenona</span></td><td>25 ‚Äì 100</td><td>1</td><td>Mais seletivo (menos ginecomastia).</td></tr>
                    <tr><td><span class="drug-name">Amilorida</span></td><td>2,5 ‚Äì 5</td><td>1</td><td>Geralmente em associa√ß√£o.</td></tr>
                </table>

                <h4 style="color:#00796B; margin-bottom:0;">2. Inibidores da ECA (IECA) (A)</h4>
                <div class="drug-class-info"><strong>Obs. Classe:</strong> Indicados em DM, DRC, ICFER. Risco de tosse seca, hipercalemia e angioedema. <strong>Contraindicados na gesta√ß√£o</strong>.</div>
                <table class="drug-table">
                    <tr><th>F√°rmaco</th><th>Dose (mg)</th><th>x/dia</th><th>Obs</th></tr>
                    <tr><td><span class="drug-name">Captopril <span class="tag-sus">SUS</span></span></td><td>25 ‚Äì 150</td><td>2 a 3</td><td>Meia-vida curta. Uso em urg√™ncias.</td></tr>
                    <tr><td><span class="drug-name">Enalapril <span class="tag-sus">SUS</span></span></td><td>5 ‚Äì 40</td><td>1 a 2</td><td>Padr√£o ouro no SUS.</td></tr>
                    <tr><td><span class="drug-name">Ramipril</span></td><td>2,5 ‚Äì 20</td><td>1 a 2</td><td></td></tr>
                    <tr><td><span class="drug-name">Lisinopril</span></td><td>10 ‚Äì 40</td><td>1</td><td>Contraindicado na estenose bilateral de art. renal.</td></tr>
                    <tr><td><span class="drug-name">Perindopril</span></td><td>4 ‚Äì 16</td><td>1</td><td></td></tr>
                    <tr><td><span class="drug-name">Benazepril</span></td><td>10 ‚Äì 40</td><td>1 a 2</td><td></td></tr>
                    <tr><td><span class="drug-name">Fosinopril</span></td><td>10 ‚Äì 40</td><td>1 a 2</td><td>Excre√ß√£o compensat√≥ria (√∫til em DRC).</td></tr>
                </table>

                <h4 style="color:#00796B; margin-bottom:0;">3. Bloq. Receptor Angiotensina (BRA) (A)</h4>
                <div class="drug-class-info"><strong>Obs. Classe:</strong> Alternativa aos IECAs (sem tosse). Mesmas indica√ß√µes. <strong>Nunca associar IECA + BRA</strong>.</div>
                <table class="drug-table">
                    <tr><th>F√°rmaco</th><th>Dose (mg)</th><th>x/dia</th><th>Obs</th></tr>
                    <tr><td><span class="drug-name">Losartana <span class="tag-sus">SUS</span></span></td><td>50 ‚Äì 100</td><td>1 a 2</td><td>Efeito uricos√∫rico leve.</td></tr>
                    <tr><td><span class="drug-name">Valsartana</span></td><td>80 ‚Äì 320</td><td>1</td><td></td></tr>
                    <tr><td><span class="drug-name">Candesartana</span></td><td>8 ‚Äì 32</td><td>1</td><td></td></tr>
                    <tr><td><span class="drug-name">Olmesartana</span></td><td>20 ‚Äì 40</td><td>1</td><td></td></tr>
                    <tr><td><span class="drug-name">Telmisartana</span></td><td>40 ‚Äì 80</td><td>1</td><td>Maior meia-vida da classe.</td></tr>
                    <tr><td><span class="drug-name">Irbesartana</span></td><td>150 ‚Äì 300</td><td>1</td><td></td></tr>
                </table>

                <h4 style="color:#00796B; margin-bottom:0;">4. Bloq. Canal de C√°lcio (BCC) (C)</h4>
                <div class="drug-class-info"><strong>Obs. Classe:</strong> Prefer√™ncia em negros e idosos. Dihidropirid√≠nicos (DHP) causam edema maleolar. N√£o-DHP s√£o bradicardizantes e devem ser evitados em ICFER e BAV.</div>
                <table class="drug-table">
                    <tr><th>F√°rmaco</th><th>Dose (mg)</th><th>x/dia</th><th>Obs</th></tr>
                    <tr><td><span class="drug-name">Anlodipino <span class="tag-sus">SUS</span></span></td><td>2,5 ‚Äì 10</td><td>1</td><td>DHP. Longa a√ß√£o.</td></tr>
                    <tr><td><span class="drug-name">Levanlodipino</span></td><td>2,5 ‚Äì 5</td><td>1</td><td>DHP. Is√¥mero.</td></tr>
                    <tr><td><span class="drug-name">Nifedipino</span></td><td>10 ‚Äì 60</td><td>1 a 3</td><td>DHP. N√£o usar c√°psula a√ß√£o r√°pida.</td></tr>
                    <tr><td><span class="drug-name">Felodipino</span></td><td>2,5 ‚Äì 10</td><td>1</td><td>DHP.</td></tr>
                    <tr><td><span class="drug-name">Nitrendipino</span></td><td>10 ‚Äì 30</td><td>1</td><td>DHP.</td></tr>
                    <tr><td><span class="drug-name">Manidipino</span></td><td>10 ‚Äì 20</td><td>1</td><td>DHP. Menor risco de edema.</td></tr>
                    <tr><td><span class="drug-name">Lercanidipino</span></td><td>10 ‚Äì 20</td><td>1</td><td>DHP. Lipof√≠lico, menor edema.</td></tr>
                    <tr><td><span class="drug-name">Lacidipino</span></td><td>2 ‚Äì 6</td><td>1</td><td>DHP.</td></tr>
                    <tr><td><span class="drug-name">Verapamil</span></td><td>120 ‚Äì 360</td><td>1 a 2</td><td>N√£o-DHP.</td></tr>
                    <tr><td><span class="drug-name">Diltiazem</span></td><td>80 ‚Äì 240</td><td>1 a 2</td><td>N√£o-DHP.</td></tr>
                </table>

                <h4 style="color:#00796B; margin-bottom:0;">5. Beta-bloqueadores (B)</h4>
                <div class="drug-class-info"><strong>Obs. Classe:</strong> Indica√ß√µes precisas: IC, Coronariopatia, Arritmia. N√£o s√£o 1¬™ linha em HAS pura. Risco de broncoespasmo (asma).</div>
                <table class="drug-table">
                    <tr><th>F√°rmaco</th><th>Dose (mg)</th><th>x/dia</th><th>Obs</th></tr>
                    <tr><td><span class="drug-name">Atenolol <span class="tag-sus">SUS</span></span></td><td>50 ‚Äì 100</td><td>1 a 2</td><td>Cardiosseletivo.</td></tr>
                    <tr><td><span class="drug-name">Propranolol</span></td><td>80 ‚Äì 320</td><td>2 a 3</td><td>N√£o seletivo. Mais efeitos adversos.</td></tr>
                    <tr><td><span class="drug-name">Carvedilol <span class="tag-sus">SUS</span></span></td><td>6,25 ‚Äì 50</td><td>1 a 2</td><td>Vasodilatador (Alfa+Beta). Bom para IC.</td></tr>
                    <tr><td><span class="drug-name">Metoprolol (Succinato) <span class="tag-sus">SUS</span></span></td><td>50 ‚Äì 200</td><td>1</td><td>Cardiosseletivo. Libera√ß√£o controlada (ICFER).</td></tr>
                    <tr><td><span class="drug-name">Bisoprolol</span></td><td>5 ‚Äì 20</td><td>1</td><td>Cardiosseletivo.</td></tr>
                    <tr><td><span class="drug-name">Nebivolol</span></td><td>5 ‚Äì 10</td><td>1</td><td>Vasodilatador (NO). Menor disfun√ß√£o er√©til.</td></tr>
                    <tr><td><span class="drug-name">Nadolol</span></td><td>40 ‚Äì 160</td><td>1</td><td>N√£o seletivo.</td></tr>
                    <tr><td><span class="drug-name">Pindolol</span></td><td>10 ‚Äì 60</td><td>2</td><td>Com ativ. simpaticomim√©tica intr√≠nseca (ASI).</td></tr>
                </table>

                <h4 style="color:#00796B; margin-bottom:0;">6. Agonistas Centrais e Vasodilatadores</h4>
                <div class="drug-class-info"><strong>Obs. Classe:</strong> Agonistas centrais (Clonidina/Metildopa) podem causar sonol√™ncia e boca seca. Vasodilatadores diretos (Hidralazina/Minoxidil) causam reten√ß√£o h√≠drica e taquicardia reflexa (associar diur√©tico + BB).</div>
                <table class="drug-table">
                    <tr><th>F√°rmaco</th><th>Dose (mg)</th><th>x/dia</th><th>Obs</th></tr>
                    <tr><td><span class="drug-name">Clonidina <span class="tag-sus">SUS</span></span></td><td>0,2 ‚Äì 0,9</td><td>2 a 3</td><td>Risco de rebote na retirada abrupta.</td></tr>
                    <tr><td><span class="drug-name">Metildopa <span class="tag-sus">SUS</span></span></td><td>500 ‚Äì 2000</td><td>2 a 3</td><td>Escolha na gesta√ß√£o.</td></tr>
                    <tr><td><span class="drug-name">Hidralazina <span class="tag-sus">SUS</span></span></td><td>50 ‚Äì 200</td><td>2 a 3</td><td>Vasodilatador direto.</td></tr>
                    <tr><td><span class="drug-name">Minoxidil</span></td><td>5 ‚Äì 40</td><td>1</td><td>Potente. Risco de hirsutismo.</td></tr>
                    <tr><td><span class="drug-name">Doxazosina</span></td><td>1 ‚Äì 16</td><td>1</td><td>Alfa-bloqueador. Bom para HPB.</td></tr>
                    <tr><td><span class="drug-name">Prazosina</span></td><td>1 ‚Äì 20</td><td>2 a 3</td><td>Risco de hipotens√£o ortost√°tica (iniciar √† noite).</td></tr>
                    <tr><td><span class="drug-name">Terazosina</span></td><td>1 ‚Äì 20</td><td>1</td><td>Alfa-bloqueador.</td></tr>
                </table>

            </div>
        </div>

        <div class="resumo-box">
            <div class="res-header">üìà Fluxograma Terap√™utico</div>
            <div class="res-content">
                <div class="step-box">
                    <span class="step-num">PASSO 1</span> <strong>Monoterapia</strong>
                    <p style="margin:5px 0 0 0; font-size:0.9rem;">
                        <strong>Indica√ß√£o:</strong> Est√°gio 1 (Risco Baixo/Moderado) ou Idoso Fr√°gil.<br>
                        <em>Op√ß√µes: IECA, BRA, BCC ou Diur√©tico.</em>
                    </p>
                </div>

                <div class="step-box">
                    <span class="step-num">PASSO 2</span> <strong>Terapia Dupla</strong>
                    <p style="margin:5px 0 0 0; font-size:0.9rem;">
                        <strong>Quem j√° inicia aqui?</strong> Est√°gio 2, Est√°gio 3 ou Est√°gio 1 (Alto Risco CV).<br>
                        <em>Esquema: (IECA ou BRA) + (BCC ou Diur√©tico).</em>
                    </p>
                </div>

                <div class="step-box">
                    <span class="step-num">PASSO 3</span> <strong>Terapia Tripla ou Otimiza√ß√£o</strong>
                    <p style="margin:5px 0 0 0; font-size:0.9rem;">
                        Se meta n√£o atingida no Passo 2.<br>
                        <strong>A√ß√£o:</strong> Otimizar doses ou associar 3¬∫ f√°rmaco.<br>
                        <em>Esquema: IECA/BRA + BCC + Diur√©tico.</em>
                    </p>
                </div>

                <div class="step-box">
                    <span class="step-num">PASSO 4</span> <strong>HAS Resistente</strong>
                    <p style="margin:5px 0 0 0; font-size:0.9rem;">
                        Sem controle com 3 drogas em dose otimizada (incluindo diur√©tico).<br>
                        <strong>Adicionar:</strong> Espironolactona 25-50mg.
                    </p>
                </div>

                <div class="step-box">
                    <span class="step-num">PASSO 5</span> <strong>Refratariedade</strong>
                    <p style="margin:5px 0 0 0; font-size:0.9rem;">
                        Falha ap√≥s adi√ß√£o de Espironolactona.<br>
                        <strong>Adicionar:</strong> Beta-bloqueador, Clonidina, Doxazosina ou Hidralazina.
                    </p>
                </div>
            </div>
        </div>

        <div class="resumo-box">
            <div class="res-header">üéØ Metas Terap√™uticas</div>
            <div class="res-content">
                <table class="table-custom">
                    <tr><th>Popula√ß√£o</th><th>Meta (mmHg)</th></tr>
                    <tr><td><strong>Geral (Risco Baixo/Mod)</strong></td><td>< 140/90</td></tr>
                    <tr><td><strong>Alto Risco CV / DM / DRC</strong></td><td>< 130/80</td></tr>
                    <tr><td><strong>Idoso H√≠gido</strong></td><td>< 140/90 (Ideal 130-139 PAS)</td></tr>
                    <tr><td><strong>Idoso Fr√°gil</strong></td><td>< 150/90 (Evitar < 120/70)</td></tr>
                </table>
            </div>
        </div>

        <div class="ref-section">
            <strong>Refer√™ncia:</strong><br>
            Brand√£o AA, Rodrigues CIS, Bortolotto LA, et al. Diretriz Brasileira de Hipertens√£o Arterial - 2025. Arq Bras Cardiol. 2025.
        </div>

    </div>

</body>
</html>